From Measurement to Management ― Lipoprotein(a) After Acute Coronary Syndrome ―
Open Access
- 12 March 2026
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (8) , CJ-26-0092-998
Abstract
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.Keywords
This publication has 15 references indexed in Scilit:
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasAtherosclerosis, 2025
- Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndromeJournal of Clinical Lipidology, 2024
- Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery diseaseEuropean Journal of Clinical Investigation, 2023
- Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndromeIJC Heart & Vasculature, 2022
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statementEuropean Heart Journal, 2022
- Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of IndiaJournal of Clinical Lipidology, 2022
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialEuropean Heart Journal, 2020
- Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―Circulation Journal, 2020
- Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population studyAtherosclerosis, 2017
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009